Skip to content

Wave Life Sciences WVE Enterprise value

Enterprise value at other companies

Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$2.02B-67.2%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$12.92B+175%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$12.15B+67.5%
ALN
Alnylam PharmaceuticalsALNY
$42.43B+24.1%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$2.39B+51.2%

Other financials

Income statement

See full
Revenue$38.2M+317%
Operating income-$31.3M+37.2%
Net income-$26.1M+44.4%
EPS (diluted)-$0.13+55.2%

Balance sheet

See full
Cash & equivalents$544.6M+124%
Total debt$15.7M-33.4%
Total equity$511.7M+198%
Total assets$583.5M+102%

Cash flow

See full
Operating cash flow-$59.6M+5.5%
CapEx$438.0K+165%
Free cash flow-$60.0M+5.1%

Valuation

See full
Market cap$1.14B+13.0%
P/S15.1×-12.2×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-53.7%
Debt / equity-0.1×
Current ratio11.3×+8.3×

Where this comes from

Calculated from Wave Life Sciences’s reported figures.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Wave Life Sciences's enterprise value?
Wave Life Sciences (WVE) reported enterprise value of $835.97M in Q1 2026.
How has Wave Life Sciences's enterprise value changed year-over-year?
Wave Life Sciences's enterprise value decreased by 18.1% year-over-year, from $1.02B to $835.97M.
What is the long-term trend for Wave Life Sciences's enterprise value?
Over 5 years (2020 to 2025), Wave Life Sciences's enterprise value has grown at a 52.9% compound annual growth rate (CAGR), from $307.82M to $2.57B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.